S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q4 2025

Baker Bros Advisors

Periodo: Q4 2025 · Depositato: 2026-02-17
Vedi su SEC EDGAR
AUM
$17.08B
Valore totale del portafoglio
Posizioni
86
Titoli dichiarati
Prima Posizione
INCY
17.8% $3.04B
Var. Trimestrali
+8 / -8
nuovi · usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR — non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquidità, obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato è il valore nozionale delle azioni sottostanti — non il premio pagato. Ciò sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo è tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con ≥$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker è a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2026-02-17) si riferisce al titolo sottostante — non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
INCYIncyte Corporation$3.04B17.78%$98.77$116.86+18.3%
17.8%
ONCBeOne Medicines Ltd.$2.67B15.65%$303.81$297.65-2.0%
15.7%
MDGLMadrigal Pharmaceuticals, Inc.$1.25B7.30%$582.34$528.10-9.3%
7.3%
INSMInsmed Incorporated$1.15B6.72%$174.04$111.60-35.9%
6.7%
ACADACADIA Pharmaceuticals Inc.$1.15B6.71%$26.71$25.97-2.8%
6.7%
CELCCelcuity Inc.$789.5M4.62%$99.74$107.95+8.2%
4.6%
RVMDRevolution Medicines, Inc.$753.1M4.41%$79.65$189.24+137.6%
4.4%
KYMRKymera Therapeutics, Inc.$673.6M3.94%$77.81$113.51+45.9%
3.9%
SMMTSummit Therapeutics Inc.$636.5M3.73%$17.49$15.42-11.8%
3.7%
RYTMRhythm Pharmaceuticals, Inc.$599.9M3.51%$107.04$114.17+6.7%
3.5%
KODKodiak Sciences Inc.$556.9M3.26%$27.96$38.54+37.8%
3.3%
PRAXPraxis Precision Medicines, Inc.$332.0M1.94%$294.74$318.52+8.1%
1.9%
ALKSAlkermes plc$280.1M1.64%$27.98$54.58+95.1%
1.6%
GRALGRAIL, Inc.$178.5M1.05%$85.59$69.11-19.3%
1.1%
EWTXEdgewise Therapeutics, Inc.$163.2M0.96%$24.82$39.56+59.4%
1.0%
ARWRArrowhead Pharmaceuticals, Inc.$144.4M0.85%$66.39$83.99+26.5%
0.8%
IONSIonis Pharmaceuticals, Inc.$141.8M0.83%$79.11$81.80+3.4%
0.8%
IMVTImmunovant, Inc.$138.7M0.81%$25.42$38.79+52.6%
0.8%
IMTXImmatics N.V.$127.0M0.74%$10.50$9.95-5.2%
0.7%
IDYAIDEAYA Biosciences, Inc.$125.1M0.73%$34.57$37.65+8.9%
0.7%
ROIVRoivant Sciences Ltd.$120.5M0.71%$21.70$35.13+61.9%
0.7%
ABVXAbivax S.A.$118.1M0.69%$134.85$144.65+7.3%
0.7%
KNSAKiniksa Pharmaceuticals International, plc$116.6M0.68%$41.25$64.53+56.4%
0.7%
REPLReplimune Group, Inc.$107.4M0.63%$9.72$11.58+19.1%
0.6%
STOKStoke Therapeutics, Inc.$105.9M0.62%$31.74$32.70+3.0%
0.6%
GPCRStructure Therapeutics Inc.$99.6M0.58%$69.55$53.45-23.1%
0.6%
ABCLAbCellera Biologics Inc.$94.1M0.55%$3.42$8.11+137.1%
0.6%
NRIXNurix Therapeutics, Inc.$88.4M0.52%$18.97$23.97+26.4%
0.5%
IMCRImmunocore Holdings plc$80.6M0.47%$34.71$32.50-6.4%
0.5%
BCYCBicycle Therapeutics plc$77.1M0.45%$7.08$4.35-38.6%
0.5%

Attività Trimestre su Trimestre

Q4 2025 vs. Q3 2025

Nuove Posizioni (8)

TickerEmittenteNozionale
TERNTerns Pharmaceuticals, Inc.$38.4M
JBIOJade Biosciences, Inc.$25.3M
BCRXBioCryst Pharmaceuticals, Inc.$22.0M
CNTACentessa Pharmaceuticals plc$16.8M
DYNDyne Therapeutics, Inc.$15.9M
ABSIAbsci Corporation$7.5M
RCUSArcus Biosciences, Inc.$6.4M
MPLTMapLight Therapeutics, Inc.$6.4M

Posizioni Chiuse (8)

TickerEmittenteNozionale
MRUSMerus N.V.$54.1M
NTLAIntellia Therapeutics, Inc.$47.4M
RNAMAvidity Biosciences, Inc.$27.2M
PCVXVaxcyte, Inc.$23.1M
CDTXCidara Therapeutics, Inc.$21.8M
AKROAkero Therapeutics, Inc.$15.4M
ACLXArcellx, Inc.$13.7M
VKTXViking Therapeutics, Inc.$9.6M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
CTNMContineum Therapeutics, Inc.$15.3M+1729.3%
TECXTectonic Therapeutic, Inc.$17.3M+803.4%
CRNXCrinetics Pharmaceuticals, Inc.$65.1M+488.9%
IONSIonis Pharmaceuticals, Inc.$104.7M+216.1%+3.4%
ELVNEnliven Therapeutics, Inc.$1.8M+136.3%
VTYXVentyx Biosciences, Inc.$18.0M+129.6%
KALAKALA BIO, Inc.$-0.5M+83.1%
TARAProtara Therapeutics, Inc.$2.8M+81.0%

Ridotte (7)

TickerEmittenteNozionaleVar. AzioniDal Deposito
SANASana Biotechnology, Inc.$-6.0M-84.7%
ARGXargenx SE$-6.7M-33.3%
STOKStoke Therapeutics, Inc.$-3.0M-28.0%+3.0%
GLUEMonte Rosa Therapeutics, Inc.$31.7M-11.6%
EWTXEdgewise Therapeutics, Inc.$44.7M-10.0%+59.4%
GPCRStructure Therapeutics Inc.$56.1M-7.9%-23.1%
INSMInsmed Incorporated$182.0M-1.7%-35.9%
Torna agli Hedge Fund